Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

65.39
+2.373.76%
Post-market: 65.390.00000.00%16:10 EDT
Volume:284.06K
Turnover:18.55M
Market Cap:1.88B
PE:-142.12
High:66.01
Open:64.06
Low:64.00
Close:63.02
52wk High:68.39
52wk Low:15.40
Shares:28.75M
Float Shares:17.26M
Volume Ratio:0.36
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4601
EPS(LYR):-0.4601
ROE:-24.49%
ROA:7.06%
PB:50.52
PE(LYR):-142.12

Loading ...

AnaptysBio (ANAB): Evaluating Valuation After Phase 2 Ulcerative Colitis Trial Discontinuation and Cost Savings

Simply Wall St.
·
Nov 20, 2025

U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare

Reuters
·
Nov 13, 2025

AnaptysBio Inc : JP Morgan Cuts Target Price to $67 From $79

THOMSON REUTERS
·
Nov 13, 2025

Stock Track | AnaptysBio Plummets 5.24% as Analysts Slash Price Targets Following Phase 2 Trial Results

Stock Track
·
Nov 11, 2025

AnaptysBio : Barclays Cuts Target Price to $70 From $83

THOMSON REUTERS
·
Nov 11, 2025

TD Cowen Reaffirms Their Buy Rating on AnaptysBio (ANAB)

TIPRANKS
·
Nov 11, 2025

Barclays Keeps Their Buy Rating on AnaptysBio (ANAB)

TIPRANKS
·
Nov 11, 2025

AnaptysBio Down Over 14%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

Dow Jones
·
Nov 11, 2025

AnaptysBio price target lowered to $50 from $70 at Wedbush

TIPRANKS
·
Nov 11, 2025

AnaptysBio Is Maintained at Hold by Truist Securities

Dow Jones
·
Nov 11, 2025

Wedbush Adjusts Price Target on AnaptysBio to $50 From $70, Maintains Outperform Rating

MT Newswires Live
·
Nov 11, 2025

BUZZ-AnaptysBio falls after ulcerative colitis drug fails in mid-stage trial

Reuters
·
Nov 10, 2025

AnaptysBio Inc : Leerink Partners Cuts Target Price to $58 From $62

THOMSON REUTERS
·
Nov 10, 2025

Stock Track | AnaptysBio Plummets 19% as Rosnilimab Fails to Meet Ulcerative Colitis Trial Endpoints

Stock Track
·
Nov 10, 2025

AnaptysBio price target raised to $36 from $20 at Truist

TIPRANKS
·
Nov 10, 2025

AnaptysBio Halts Rosnilimab Ulcerative Colitis Trial After Missing Phase 2 Endpoints

Reuters
·
Nov 10, 2025

AnaptysBio Inc - Update on Rosnilimab in Ra Expected in H1 2026

THOMSON REUTERS
·
Nov 10, 2025

AnaptysBio Inc - Uc Trial Discontinued, Savings of at Least $10 Mln

THOMSON REUTERS
·
Nov 10, 2025

AnaptysBio Inc - Rosnilimab Fails to Meet Primary Endpoint in Uc Trial

THOMSON REUTERS
·
Nov 10, 2025

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

THOMSON REUTERS
·
Nov 10, 2025